Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo

Gene Therapy

Volumn 5, Issue 9, 1998, Pages 1187-1194

  Stander M ^b   Naumann, U ^a   Dumitrescu, L ^a   Heneka, M ^a   Loschmann P ^a   Gulbins, E ^a   Dichgans, J ^a   Weller, M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Medical School ^*

Author keywords

Decorin; Gene therapy; Immune system; Immune therapy; Malignant glioma; Transforming growth factor

Indexed keywords

CYTOKINE; DECORIN; MESSENGER RNA; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENE TRANSFER; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; RNA TRANSCRIPTION; T LYMPHOCYTE; TUMOR REGRESSION;

EID: 0031717878     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300709     Document Type: Article

References (24)

1. Roszman T, Elliott L, Brooks W. Modulation of T cell function by gliomas. Immunol Today 1991; 12: 370-374.
2. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T cell apoptosis, and the immune privilege of the brain. Brain Res Rev 1995; 21: 128-151.
3. 2, induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur J Immunol 1994; 24: 1293-1298.
4. Fakhrai H et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 1996; 93: 2909-2914.
5. Saas P et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-1178.
6. Weller M et al. CD95-dependent T cell killing by glioma cells expressing CD95 ligand: more on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. Cell Physiol Biochem 1997; 7: 282-288.
7. Yamaguchi Y, Mann D, Ruoslathi E. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 1990; 346: 281-284.
8. Hildebrand A et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochem J 1994; 302: 527-534.
9. Border WA et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992; 360: 361-364.
10. Isaka Y et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 1996; 4: 418-423.
11. Karasuyama H, Kudo A, Melchers F. The protein encoded by the VpreB and λ5 pre-B cell genes can associate with each other and with μ heavy chain. J Exp Med 1990; 172: 969-972.
12. Olofsson A et al. Transforming growth factor-β1, β2 and β3 secreted by human glioblastoma cell lines. J Biol Chem 1992; 267: 19481-19488.
13. 3, by glioblastoma cells, astrocytes and microglia. J Immunol 1992; 148: 1404-1410.
14. Stichel C et al. Differential expression of the small chondroitin/dermatan sulfate proteoglycans decorin and biglycan after injury of the adult rat brain. Brain Res 1995; 704: 263-274.
15. Hanemann C et al. Expression of decorin mRNA in the nervous system of rat. J Histochem Cytochem 1993; 41: 1383-1391.
16. Voss B, Glössl J, Cully Z, Kresse H. Immunocytochemical investigation on the distribution of small chondroitin sulfate-dermatan sulfate proteoglycans in human. J Histochem Cytochem 1986; 34: 1013-1019.
17. Ruoslathi E, Yamaguchi Y. Proteoglycans as modulator of growth factor activities. Cell 1991; 64: 867-869.
18. Santra M et al. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic orgin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 1997; 100: 149-157.
19. Weller M et al Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human malignant glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994; 94: 954-964.
20. Weller M et al. Proto-oncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995; 95: 2633-2643.
21. Weller M et al. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 1995; 55: 2936-2944.
22. Oike Y et al. Stuctural analysis of chick-embryo cartilage proteoglycan by selective degradation with chondroitin lyases (chondroitinases) and endo-β-D-galactosidase (keratanase). Biochem J 1980; 191: 193-207.
23. Garrigue-Antar L et al. Optimisation of CCL64-based bioassay for TGF-beta. J Immunol Meth 1995; 186: 267-274.
24. Esser P et al. Apoptosis in proliferative vitreoretinal disorders. Possible involvement of TGF-β-induced RPE cell apoptosis. Exp Eye Res 1997; 65: 365-378.